All News
Filter News
Found 2,306 articles
-
Flagship Pioneering Catalyzes Growth With New Leadership Appointments
2/1/2018
Flagship Pioneering today announcing the appointment of two new partners: Rob Rosiello, executive partner and chief operating officer, and Jason Pontin, senior partner and chief editor.
-
Avacta and OncoSec to Collaborate on Innovative Gene Delivery of Therapeutic Affimers
1/22/2018
The research programme will evaluate the benefits of delivering Affimer protein genes directly into tumors using the OncoSec technology with the long-term aim of developing gene delivered Affimer immunotherapies.
-
Moderna unleashed a torrent of updates yesterday.
-
Adimab Provides Year-End Update on 2017 Partnership Activities
1/8/2018
Adimab today announced that in 2017 it entered into agreements with seven new companies.
-
Perosphere Pharmaceuticals Appoints Robert S. Langer, Sc.D. to its Board of Directors
1/8/2018
Perosphere Pharmaceuticals Inc. announced today that it has appointed Robert S. Langer, Sc.D., founding Chairman of Perosphere's Scientific Advisory Board and Institute Professor, MIT, to its Board of Directors.
-
The Series A round was entirely funded by founding investor Apple Tree Partners.
-
Dr. Mendlein will be responsible for corporate strategy, product advancement and strategy, partnering and product protection.
-
Kaleido Biosciences Announces Appointment of Wendy Arnold as Senior Vice President, Human Resources
1/3/2018
Ms. Arnold, who brings more than 20 years of experience in human resources to Kaleido, will report directly to chief executive officer and chair, Michael Bonney.
-
Moderna to Provide Corporate and Pipeline Updates and Outline Strategic Priorities at 2018 J.P. Morgan Healthcare Conference
1/2/2018
Mr. Bancel’s presentation will take place on Monday, January 8, 2018 at 2:30 p.m. PT in Elizabethan Room C/D at The Westin St. Francis Hotel in San Francisco.
-
The total capital raised by Flagship to fuel its institutional innovation and venture creation platform now exceeds $2.3B.
-
Moderna Publishes Preclinical Data in Cell Reports on mRNA Therapeutic to Treat Rare Liver Disease Methylmalonic Acidemia (MMA), A Disorder of Organic Acid Metabolism
12/20/2017
Moderna announced the publication of preclinical data supporting its first rare liver disease development program, an mRNA therapeutic for methylmalonic acidemia (MMA), a serious and often life-threatening organic acidemia.
-
Indiana University School of Medicine Researchers Identify First Brain Training Exercise Positively Linked to Dementia Prevention
11/17/2017
The cognitive training, called speed of processing, showed benefits up to 10 years after study participants underwent the mental exercise program, said Frederick W. Unverzagt, PhD, professor of psychiatry at Indiana University School of Medicine.
-
Moderna announced that it has dosed its first patient in a Phase I trial of mRNA-4157, a mRNA-based personalized cancer vaccine.
-
Evox Therapeutics Appoints Antonin de Fougerolles as Chief Executive Officer
11/13/2017
Experienced life sciences executive with strong history of successful advancement of novel drug platforms and pipeline development [13-November-2017] OXFORD, England, November 13, 2017 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the appointment of Dr Antonin &quo
-
Syros Announces Appointment of Jeremy P. Springhorn as Chief Business Officer
11/13/2017
Dr. Springhorn will hold broad management responsibility for business development and strategic planning.
-
Two of the top companies in the field are German-based CureVac and U.S.-based Moderna Therapeutics.
-
5th International mRNA Health Conference Highlights Rapid Clinical Progress and Cross-Industry Collaboration
11/6/2017
The International mRNA Health Conference, the premier meeting destination for professionals and academics in the field of mRNA drugs, celebrated the success of its 5th annual event held in Berlin, Germany on November 1–2.
-
Moderna CEO said the company was not likely to float its initial public offering until the company has solid data on its lead mRNA treatment.
-
The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
-
Eli Lilly has signed a collaboration deal with CureVac that could total up to $1.8B.